http://www.jstage.js...1_1727/_articleNeurotrophic factors are essential to maintain and organize neurons functionally; thereby neurotrophic factor-like substances or their inducers are expected to be applied to the treatment of neurodegenerative diseases such as Alzheimer's disease. In the present study, we firstly examined
the effects of ethanol extracts of four edible mushrooms,
Hericium erinaceus (Yamabushitake),
Pleurotus eryngii (Eringi),
Grifola frondosa (Maitake), and
Agaricus blazei (Himematsutake), on nerve growth factor (NGF) gene expression in 1321N1 human astrocytoma cells. Among the four mushroom extracts, only
H. erinaceus extract promoted NGF mRNA expression in a concentration-dependent manner. In addition, secretion of NGF protein from 1321N1 cells was enhanced by
H. erinaceus extracts, and the conditioned medium of 1321N1 cells incubated with
H. erinaceus extract enhanced the neurite outgrowth of PC12 cells. However, hericenones C, D and E, constituents of
H. erinaceus, failed to promote NGF gene expression in 1321N1 cells. The enhancement of NGF gene expression by
H. erinaceus extracts was inhibited by the c-jun N-terminal kinase (JNK) inhibitor SP600125. In addition,
H. erinaceus extracts induced phosphorylation of JNK and its downstream substrate c-Jun, and increased c-fos expression, suggesting that
H. erinaceus promotes NGF gene expression
via JNK signaling. Furthermore we examined the efficacy of
H. erinaceus in vivo. ddY mice given feed containing 5%
H. erinaceus dry powder for 7 d showed an increase in the level of NGF mRNA expression in the hippocampus. In conclusion,
H. erinaceus contains active compounds that stimulate NGF synthesis
via activation of the JNK pathway; these compounds are not hericenones.
Ethanol extract.
Phytother Res. 2009 Mar;23(3):367-72.
Improving effects of the mushroom Yamabushitake (Hericium erinaceus) on mild cognitive impairment: a double-blind placebo-controlled clinical trial.Mori K,
Inatomi S,
Ouchi K,
Azumi Y,
Tuchida T.
SourceMushroom Laboratory, Hokuto Corporation, 800-8, Shimokomazawa, Nagano, 381-0008, Japan. morikou@mail2.pharm.tohoku.ac.jp
AbstractA double-blind, parallel-group, placebo-controlled trial was performed on 50- to 80-year-old Japanese men and women diagnosed with mild cognitive impairment in order to examine the efficacy of oral administration of Yamabushitake (
Hericium erinaceus), an edible mushroom, for improving cognitive impairment, using a cognitive function scale based on the Revised Hasegawa Dementia Scale (HDS-R). After 2 weeks of preliminary examination, 30 subjects were randomized into two 15-person groups, one of which was given Yamabushitake and the other given a placebo. The subjects of the Yamabushitake group took four 250 mg tablets containing 96% of Yamabushitake dry powder three times a day for 16 weeks. After termination of the intake, the subjects were observed for the next 4 weeks. At weeks 8, 12 and 16 of the trial, the Yamabushitake group showed significantly increased scores on the cognitive function scale compared with the placebo group. The Yamabushitake group's scores increased with the duration of intake, but at week 4 after the termination of the 16 weeks intake, the scores decreased significantly. Laboratory tests showed no adverse effect of Yamabushitake. The results obtained in this study suggest that Yamabushitake is effective in improving mild cognitive impairment.
PMID:18844328http://www.ncbi.nlm.nih.gov/pubmed/18844328
The mushroom contains heavy metals.
Assessment of heavy metals in some wild edible mushrooms collected from Yunnan Province, China.http://www.ncbi.nlm....pubmed/20976551
Edited by Ichoose2live, 05 August 2011 - 04:52 AM.